Critical Limb Ischemia (CLI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Critical limb ischemia (CLI) represents the most severe manifestation of peripheral artery disease, characterized by chronic ischemic rest pain, ulceration, or gangrene due to peripheral arterial vessel occlusion. Diagnosis of CLI relies on clinical assessments, including the ankle-brachial index (ABI), toe systolic pressure, and transcutaneous oxygen pressure (TcPO2). CLI diagnosis is confirmed when ischemic rest pain coexists with an ankle pressure <50 mmHg or a toe pressure <30 mmHg, or in patients with foot ulcers or gangrene exhibiting an ankle pressure <70 mmHg, a toe systolic pressure <50 mmHg, or TcPO2 <30 mmHg. CLI typically arises from multi-segmental peripheral artery disease, resulting in compromised blood flow to peripheral tissues. Concurrent impairment in cardiac output can exacerbate peripheral perfusion in CLI patients. Diminished tissue oxygenation and nutrition may lead to claudication or rest pain, although these symptoms may be attenuated or absent in diabetic patients with neuropathy. Diabetic CLI patients often present with distal arterial lesions below the knee (BTK), with ulceration, necrosis, or gangrene being the initial signs of PAD. Chronic critical limb ischemia culminates from arterial occlusive disease, primarily atherosclerosis, often in conjunction with hypertension, hypercholesterolemia, smoking, or diabetes. Less common causes include Buerger's disease (thromboangiitis obliterans) and certain arteritis forms. The overarching objective of CLI management is to alleviate pain, facilitate wound healing, enhance patient functionality, avert limb amputation, and decrease mortality. Lower limb revascularization is the frontline treatment for CLI patients deemed suitable for the procedure. However, in select cases where patients have multiple comorbidities or a low likelihood of successful revascularization, primary amputation may be necessary.

Thelansis’s “Critical Limb Ischemia (CLI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Critical Limb Ischemia (CLI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Critical Limb Ischemia (CLI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Critical Limb Ischemia (CLI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Critical Limb Ischemia (CLI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033